UNIVERSITY PARK, Pa., April 15 -- Pennsylvania State University issued the following news release:
HERSHEY, Pa. - A new clinical trial led by the Penn State College of Medicine-based Beat Childhood Cancer Research Consortium will evaluate whether the drug eflornithine (DFMO) can help prevent relapse and improve outcomes for patients with Ewing sarcoma and osteosarcoma - two aggressive bone cancers that have seen few meaningful treatment advances in decades, according to Giselle Saulnier Sholler, chair and founder of the consortium.
Sholler, also the Four Diamonds Endowed Chair for Pediatric Oncology Research in the Department of Pediatrics and a professor of neuroscience and experimental therapeutics, said the trial aims to build on recen...